更年期荷尔蒙疗法与乳腺癌之间的关系仍未确定。

IF 503.1 1区 医学 Q1 ONCOLOGY
Mike Fillon
{"title":"更年期荷尔蒙疗法与乳腺癌之间的关系仍未确定。","authors":"Mike Fillon","doi":"10.3322/caac.21843","DOIUrl":null,"url":null,"abstract":"<p>It has been more than 2 decades since the Women’s Health Initiative (WHI; https://www.whi.org/) alarmed clinicians with a report that found that the combination of conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA), when administered to postmenopausal women, increased breast cancer risk as well as the risks for coronary heart disease, stroke, and total mortality without improving quality of life. Since then, several researchers have questioned the findings, and the overarching conclusions have been revisited by WHI investigators themselves. Despite this, clinicians and their patients continue to take on a “safer rather than sorry” stance and often decide against taking the menopausal hormone therapy (HT), regardless of what symptoms may be present.</p><p>For example, in a study appearing in the journal Menopause: The Journal of The Menopause Society in April 2023 (doi:10.1097/GME.0000000000002154), WHI investigators conceded that HT yielded considerable benefits. However, they continued to assert that the associated increase in the risk of breast cancer with combined HT (CEE and MPA) remained a valid concern.</p><p>In response, a review published in the journal sought to rectify the association between breast cancer and HT—both CEE alone and CEE in combination with MPA, a large source of the misinterpretation (doi:10.1097/GME.0000000000002267). One of the authors, Avrum Z. Bluming, MD, an oncologist at the Keck School of Medicine at the University of Southern California in Los Angeles, explains it this way: “According to WHI’s own data, estrogen alone significantly decreases the risk of breast cancer development (by 23%) and the risk of breast cancer death (by 40%)—crucial information for women who have had hysterectomies.” In addition, “when started within 10 years of a woman’s final period (the ‘window of opportunity’), the WHI now agrees,” says Dr Bluming, that “it significantly decreases the risk for coronary heart disease, improves longevity, is the best and safest treatment for menopausal symptoms, and does not increase the risk of stroke. Further, it decreases the risk of osteoporotic hip fracture, colon cancer, and diabetes mellitus.” The sole issue at play is the association between combined HT (CEE plus MPA) and the risk of breast cancer.</p><p>In their review, Dr Bluming and his colleagues write that “the association between combined HT and an ‘increased breast cancer risk’ is actually not statistically significant. Further, even if one were to accept that the WHI’s claims of an increased risk were accurate, that increase would amount to one additional case of breast cancer for every 1,000 women treated per year but no increase in the risk of dying from breast cancer.” In addition, they argue that the assertion from WHI investigators that there is an association between the declining incidence of breast cancer and the reduction in HT prescriptions is not supported by several lines of data, including the fact that the decline in breast cancer incidence in the United States actually predated the release of the WHI’s results.</p><p>Dr Bluming and his colleagues are concerned that the WHI investigators’ 2023 article, by minimizing and deflecting repeated substantive criticisms, prolongs the worry so deeply felt by women and physicians and the resulting underutilization of HT at the expense of women’s health. “As a new generation of women ponders the benefits and risks of HT,” they conclude, “with breast cancer fear as a driving factor in women’s health choices, it is time to be honest about these findings from WHI.”</p><p>“This analysis is provocative,” says Joshua D. Safer, MD, a professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, New York. “It does not change all the messages we’ve received and believed from WHI, but it does a good job of highlighting that the women treated with estrogen had benefit with regard to breast cancer risk—a key point that has been buried for years.”</p><p>“I think this review is important in that it makes us reconsider what the risks and benefits are if you’ve prescribed—or are considered prescribing—systemic hormone replacement therapy for women with menopause,” says Ellie Proussaloglou, MD, an assistant professor of surgery (breast surgical oncology) at Yale University in New Haven, Connecticut. “This review addresses whether we are undertreating women with systemic menopausal symptoms, and what’s the impact of that? This is very important as we responsibly consider what the data actually tells us about cancer risk.</p><p>“The advice that I give to my patients, and the advice I give to clinicians I meet is to have a really nuanced conversation about the symptoms their patient is experiencing, what breast cancer risks are factoring into that decision making, such as family history and personal factors, and then to strike a balance,” adds Dr Proussaloglou, who is also the physician lead for high-risk breast care in the Division of Cancer Genetics and Prevention at Smilow Cancer Hospital in New Haven, Connecticut. “Too often, we have patients who are told concretely—by their physicians—that HT therapy is bad—it increases your breast cancer risk; this doesn’t account for all of the other medical benefits of HRT [hormone replacement therapy] and quality-of-life factors that impact women during menopause. It also doesn’t account for differential risk from specific hormone formulations.”</p><p>Dr Proussaloglou says that oncologists should think about the use of HT separately for patients who have cancer and patients who have not had cancer. “It is important to distinguish patient groups into people who do not have cancer, for whom I think the existing data in this article and other research indicates that HT is not this terrible option that we thought, and those who do have cancer. Of course, for patients with cancer it’s a different conversation regarding risks of hormone replacement.”</p><p>“A takeaway from this study is humility,” says Dr Safer, who is also the executive director of the Mount Sinai Center for Transgender Medicine and Surgery. “Some of what we’ve believed we’ve known regarding the connection between breast cancer and exogenous estrogens may be a connection between breast cancer and exogenous progestogens instead. It’s just that most studies examine both agents together due to concern for cancer risk with unopposed exogenous estrogens. It is interesting to consider that the breast cancer risk may not be higher for women who take estrogen/progestogen combination therapy—the opposite of what many have thought.</p><p>“Even if that were not true, it would be still true that estrogen seems to protect against breast cancer in some instances, while progestogens mitigate or completely reverse that benefit. That means perhaps we should be encouraging women who don’t have a uterus, and therefore who can take estrogens without progestogens, to take estrogens as they pass typical menopause age. That could be true for both transgender women and for cisgender women who have had a hysterectomy.”</p><p>Dr Bluming says that he is realistic about how his and his colleagues’ critique will be received. “This paper (itself) should generate considerable controversy.” He believes that the takeaway message is best stated in the conclusion of the article:</p><p>“If WHI had transparently reported their breast cancer findings in 2002, emphasizing, among other things, a lack of statistical significance in breast cancer risk in the per-protocol adjusted statistic; had quickly followed up by publishing a per-protocol analysis adjusting for baseline breast cancer risk factors; and had reminded the public that its findings did not apply to women initiating HT in perimenopause or early post-menopause, there would have been minimal controversy, no confusion, and women’s health would not have suffered so dramatically over the ensuing decades.”</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":null,"pages":null},"PeriodicalIF":503.1000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21843","citationCount":"0","resultStr":"{\"title\":\"The association between menopausal hormone therapy and breast cancer remains unsettled\",\"authors\":\"Mike Fillon\",\"doi\":\"10.3322/caac.21843\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>It has been more than 2 decades since the Women’s Health Initiative (WHI; https://www.whi.org/) alarmed clinicians with a report that found that the combination of conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA), when administered to postmenopausal women, increased breast cancer risk as well as the risks for coronary heart disease, stroke, and total mortality without improving quality of life. Since then, several researchers have questioned the findings, and the overarching conclusions have been revisited by WHI investigators themselves. Despite this, clinicians and their patients continue to take on a “safer rather than sorry” stance and often decide against taking the menopausal hormone therapy (HT), regardless of what symptoms may be present.</p><p>For example, in a study appearing in the journal Menopause: The Journal of The Menopause Society in April 2023 (doi:10.1097/GME.0000000000002154), WHI investigators conceded that HT yielded considerable benefits. However, they continued to assert that the associated increase in the risk of breast cancer with combined HT (CEE and MPA) remained a valid concern.</p><p>In response, a review published in the journal sought to rectify the association between breast cancer and HT—both CEE alone and CEE in combination with MPA, a large source of the misinterpretation (doi:10.1097/GME.0000000000002267). One of the authors, Avrum Z. Bluming, MD, an oncologist at the Keck School of Medicine at the University of Southern California in Los Angeles, explains it this way: “According to WHI’s own data, estrogen alone significantly decreases the risk of breast cancer development (by 23%) and the risk of breast cancer death (by 40%)—crucial information for women who have had hysterectomies.” In addition, “when started within 10 years of a woman’s final period (the ‘window of opportunity’), the WHI now agrees,” says Dr Bluming, that “it significantly decreases the risk for coronary heart disease, improves longevity, is the best and safest treatment for menopausal symptoms, and does not increase the risk of stroke. Further, it decreases the risk of osteoporotic hip fracture, colon cancer, and diabetes mellitus.” The sole issue at play is the association between combined HT (CEE plus MPA) and the risk of breast cancer.</p><p>In their review, Dr Bluming and his colleagues write that “the association between combined HT and an ‘increased breast cancer risk’ is actually not statistically significant. Further, even if one were to accept that the WHI’s claims of an increased risk were accurate, that increase would amount to one additional case of breast cancer for every 1,000 women treated per year but no increase in the risk of dying from breast cancer.” In addition, they argue that the assertion from WHI investigators that there is an association between the declining incidence of breast cancer and the reduction in HT prescriptions is not supported by several lines of data, including the fact that the decline in breast cancer incidence in the United States actually predated the release of the WHI’s results.</p><p>Dr Bluming and his colleagues are concerned that the WHI investigators’ 2023 article, by minimizing and deflecting repeated substantive criticisms, prolongs the worry so deeply felt by women and physicians and the resulting underutilization of HT at the expense of women’s health. “As a new generation of women ponders the benefits and risks of HT,” they conclude, “with breast cancer fear as a driving factor in women’s health choices, it is time to be honest about these findings from WHI.”</p><p>“This analysis is provocative,” says Joshua D. Safer, MD, a professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, New York. “It does not change all the messages we’ve received and believed from WHI, but it does a good job of highlighting that the women treated with estrogen had benefit with regard to breast cancer risk—a key point that has been buried for years.”</p><p>“I think this review is important in that it makes us reconsider what the risks and benefits are if you’ve prescribed—or are considered prescribing—systemic hormone replacement therapy for women with menopause,” says Ellie Proussaloglou, MD, an assistant professor of surgery (breast surgical oncology) at Yale University in New Haven, Connecticut. “This review addresses whether we are undertreating women with systemic menopausal symptoms, and what’s the impact of that? This is very important as we responsibly consider what the data actually tells us about cancer risk.</p><p>“The advice that I give to my patients, and the advice I give to clinicians I meet is to have a really nuanced conversation about the symptoms their patient is experiencing, what breast cancer risks are factoring into that decision making, such as family history and personal factors, and then to strike a balance,” adds Dr Proussaloglou, who is also the physician lead for high-risk breast care in the Division of Cancer Genetics and Prevention at Smilow Cancer Hospital in New Haven, Connecticut. “Too often, we have patients who are told concretely—by their physicians—that HT therapy is bad—it increases your breast cancer risk; this doesn’t account for all of the other medical benefits of HRT [hormone replacement therapy] and quality-of-life factors that impact women during menopause. It also doesn’t account for differential risk from specific hormone formulations.”</p><p>Dr Proussaloglou says that oncologists should think about the use of HT separately for patients who have cancer and patients who have not had cancer. “It is important to distinguish patient groups into people who do not have cancer, for whom I think the existing data in this article and other research indicates that HT is not this terrible option that we thought, and those who do have cancer. Of course, for patients with cancer it’s a different conversation regarding risks of hormone replacement.”</p><p>“A takeaway from this study is humility,” says Dr Safer, who is also the executive director of the Mount Sinai Center for Transgender Medicine and Surgery. “Some of what we’ve believed we’ve known regarding the connection between breast cancer and exogenous estrogens may be a connection between breast cancer and exogenous progestogens instead. It’s just that most studies examine both agents together due to concern for cancer risk with unopposed exogenous estrogens. It is interesting to consider that the breast cancer risk may not be higher for women who take estrogen/progestogen combination therapy—the opposite of what many have thought.</p><p>“Even if that were not true, it would be still true that estrogen seems to protect against breast cancer in some instances, while progestogens mitigate or completely reverse that benefit. That means perhaps we should be encouraging women who don’t have a uterus, and therefore who can take estrogens without progestogens, to take estrogens as they pass typical menopause age. That could be true for both transgender women and for cisgender women who have had a hysterectomy.”</p><p>Dr Bluming says that he is realistic about how his and his colleagues’ critique will be received. “This paper (itself) should generate considerable controversy.” He believes that the takeaway message is best stated in the conclusion of the article:</p><p>“If WHI had transparently reported their breast cancer findings in 2002, emphasizing, among other things, a lack of statistical significance in breast cancer risk in the per-protocol adjusted statistic; had quickly followed up by publishing a per-protocol analysis adjusting for baseline breast cancer risk factors; and had reminded the public that its findings did not apply to women initiating HT in perimenopause or early post-menopause, there would have been minimal controversy, no confusion, and women’s health would not have suffered so dramatically over the ensuing decades.”</p>\",\"PeriodicalId\":137,\"journal\":{\"name\":\"CA: A Cancer Journal for Clinicians\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":503.1000,\"publicationDate\":\"2024-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21843\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CA: A Cancer Journal for Clinicians\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.3322/caac.21843\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.3322/caac.21843","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

妇女健康倡议(WHI; https://www.whi.org/)的一份报告向临床医生敲响了警钟,该报告发现,绝经后妇女联合使用共轭马雌激素(CEE)和醋酸甲羟孕酮(MPA)会增加患乳腺癌的风险以及冠心病、中风和总死亡率的风险,同时不会提高生活质量,而这一结论距今已有二十多年。此后,一些研究人员对这一研究结果提出了质疑,WHI 研究人员自己也对总体结论进行了重新审视。尽管如此,临床医生和他们的病人仍然采取 "宁可信其有,不可信其无 "的立场,经常决定不接受更年期激素治疗(HT),而不管可能出现的症状是什么:例如,在 2023 年 4 月发表于《更年期:更年期协会期刊》(doi:10.1097/GME.0000000000002154)上的一项研究中,WHI 的调查人员承认激素疗法产生了相当大的益处。作为回应,该杂志发表了一篇综述,试图纠正乳腺癌与 HT(单独 CEE 和 CEE 与 MPA 联用)之间的关联,这是造成误读的主要原因(doi:10.1097/GME.0000000000002267)。作者之一、洛杉矶南加州大学凯克医学院肿瘤学家 Avrum Z. Bluming 医学博士是这样解释的:"根据 WHI 自身的数据,单用雌激素可显著降低乳腺癌发病风险(降低 23%)和乳腺癌死亡风险(降低 40%)--这对切除子宫的妇女来说是至关重要的信息。此外,布卢明博士说:"如果在妇女末次月经的 10 年内('机会之窗')开始服用,WHI 现在一致认为,它能显著降低患冠心病的风险,延长寿命,是治疗更年期症状的最佳和最安全的方法,而且不会增加中风的风险。此外,它还能降低骨质疏松性髋部骨折、结肠癌和糖尿病的风险"。布卢明博士及其同事在他们的综述中写道:"综合 HT 与'乳腺癌风险增加'之间的关联实际上在统计学上并不显著。此外,即使人们接受 WHI 关于风险增加的说法是准确的,这种增加也相当于每年每 1000 名接受治疗的妇女中增加了一例乳腺癌病例,但死于乳腺癌的风险并没有增加"。此外,他们还认为,WHI 调查人员关于乳腺癌发病率下降与羟色胺处方减少之间存在关联的说法没有得到多方面数据的支持,其中包括美国乳腺癌发病率下降实际上早于 WHI 结果的发布。布卢明博士和他的同事们担心,WHI调查人员在2023年发表的文章,通过最小化和回避反复出现的实质性批评,延长了妇女和医生们深深感受到的担忧,以及由此导致的以牺牲妇女健康为代价的HT使用不足。"他们总结说:"在新一代女性思考高温热疗的益处和风险时,乳腺癌恐惧成为女性健康选择的驱动因素,是时候坦诚地对待WHI的这些发现了。""这项分析很有启发性,"纽约州纽约市西奈山伊坎医学院医学教授Joshua D. Safer说。"它并没有改变我们从 WHI 接收到并相信的所有信息,但它很好地强调了接受雌激素治疗的妇女在乳腺癌风险方面的益处--这是多年来一直被掩盖的关键点。"康涅狄格州纽黑文耶鲁大学外科(乳腺肿瘤外科)助理教授、医学博士 Ellie Proussaloglou 说:"我认为这篇综述很重要,因为它让我们重新考虑,如果您已经或正在考虑为更年期妇女开具系统激素替代疗法的处方,其风险和益处是什么。"这篇综述探讨了我们是否对有全身性更年期症状的女性治疗不足,以及这样做的影响是什么?这一点非常重要,因为我们要负责任地考虑有关癌症风险的数据究竟告诉了我们什么。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The association between menopausal hormone therapy and breast cancer remains unsettled

It has been more than 2 decades since the Women’s Health Initiative (WHI; https://www.whi.org/) alarmed clinicians with a report that found that the combination of conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA), when administered to postmenopausal women, increased breast cancer risk as well as the risks for coronary heart disease, stroke, and total mortality without improving quality of life. Since then, several researchers have questioned the findings, and the overarching conclusions have been revisited by WHI investigators themselves. Despite this, clinicians and their patients continue to take on a “safer rather than sorry” stance and often decide against taking the menopausal hormone therapy (HT), regardless of what symptoms may be present.

For example, in a study appearing in the journal Menopause: The Journal of The Menopause Society in April 2023 (doi:10.1097/GME.0000000000002154), WHI investigators conceded that HT yielded considerable benefits. However, they continued to assert that the associated increase in the risk of breast cancer with combined HT (CEE and MPA) remained a valid concern.

In response, a review published in the journal sought to rectify the association between breast cancer and HT—both CEE alone and CEE in combination with MPA, a large source of the misinterpretation (doi:10.1097/GME.0000000000002267). One of the authors, Avrum Z. Bluming, MD, an oncologist at the Keck School of Medicine at the University of Southern California in Los Angeles, explains it this way: “According to WHI’s own data, estrogen alone significantly decreases the risk of breast cancer development (by 23%) and the risk of breast cancer death (by 40%)—crucial information for women who have had hysterectomies.” In addition, “when started within 10 years of a woman’s final period (the ‘window of opportunity’), the WHI now agrees,” says Dr Bluming, that “it significantly decreases the risk for coronary heart disease, improves longevity, is the best and safest treatment for menopausal symptoms, and does not increase the risk of stroke. Further, it decreases the risk of osteoporotic hip fracture, colon cancer, and diabetes mellitus.” The sole issue at play is the association between combined HT (CEE plus MPA) and the risk of breast cancer.

In their review, Dr Bluming and his colleagues write that “the association between combined HT and an ‘increased breast cancer risk’ is actually not statistically significant. Further, even if one were to accept that the WHI’s claims of an increased risk were accurate, that increase would amount to one additional case of breast cancer for every 1,000 women treated per year but no increase in the risk of dying from breast cancer.” In addition, they argue that the assertion from WHI investigators that there is an association between the declining incidence of breast cancer and the reduction in HT prescriptions is not supported by several lines of data, including the fact that the decline in breast cancer incidence in the United States actually predated the release of the WHI’s results.

Dr Bluming and his colleagues are concerned that the WHI investigators’ 2023 article, by minimizing and deflecting repeated substantive criticisms, prolongs the worry so deeply felt by women and physicians and the resulting underutilization of HT at the expense of women’s health. “As a new generation of women ponders the benefits and risks of HT,” they conclude, “with breast cancer fear as a driving factor in women’s health choices, it is time to be honest about these findings from WHI.”

“This analysis is provocative,” says Joshua D. Safer, MD, a professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, New York. “It does not change all the messages we’ve received and believed from WHI, but it does a good job of highlighting that the women treated with estrogen had benefit with regard to breast cancer risk—a key point that has been buried for years.”

“I think this review is important in that it makes us reconsider what the risks and benefits are if you’ve prescribed—or are considered prescribing—systemic hormone replacement therapy for women with menopause,” says Ellie Proussaloglou, MD, an assistant professor of surgery (breast surgical oncology) at Yale University in New Haven, Connecticut. “This review addresses whether we are undertreating women with systemic menopausal symptoms, and what’s the impact of that? This is very important as we responsibly consider what the data actually tells us about cancer risk.

“The advice that I give to my patients, and the advice I give to clinicians I meet is to have a really nuanced conversation about the symptoms their patient is experiencing, what breast cancer risks are factoring into that decision making, such as family history and personal factors, and then to strike a balance,” adds Dr Proussaloglou, who is also the physician lead for high-risk breast care in the Division of Cancer Genetics and Prevention at Smilow Cancer Hospital in New Haven, Connecticut. “Too often, we have patients who are told concretely—by their physicians—that HT therapy is bad—it increases your breast cancer risk; this doesn’t account for all of the other medical benefits of HRT [hormone replacement therapy] and quality-of-life factors that impact women during menopause. It also doesn’t account for differential risk from specific hormone formulations.”

Dr Proussaloglou says that oncologists should think about the use of HT separately for patients who have cancer and patients who have not had cancer. “It is important to distinguish patient groups into people who do not have cancer, for whom I think the existing data in this article and other research indicates that HT is not this terrible option that we thought, and those who do have cancer. Of course, for patients with cancer it’s a different conversation regarding risks of hormone replacement.”

“A takeaway from this study is humility,” says Dr Safer, who is also the executive director of the Mount Sinai Center for Transgender Medicine and Surgery. “Some of what we’ve believed we’ve known regarding the connection between breast cancer and exogenous estrogens may be a connection between breast cancer and exogenous progestogens instead. It’s just that most studies examine both agents together due to concern for cancer risk with unopposed exogenous estrogens. It is interesting to consider that the breast cancer risk may not be higher for women who take estrogen/progestogen combination therapy—the opposite of what many have thought.

“Even if that were not true, it would be still true that estrogen seems to protect against breast cancer in some instances, while progestogens mitigate or completely reverse that benefit. That means perhaps we should be encouraging women who don’t have a uterus, and therefore who can take estrogens without progestogens, to take estrogens as they pass typical menopause age. That could be true for both transgender women and for cisgender women who have had a hysterectomy.”

Dr Bluming says that he is realistic about how his and his colleagues’ critique will be received. “This paper (itself) should generate considerable controversy.” He believes that the takeaway message is best stated in the conclusion of the article:

“If WHI had transparently reported their breast cancer findings in 2002, emphasizing, among other things, a lack of statistical significance in breast cancer risk in the per-protocol adjusted statistic; had quickly followed up by publishing a per-protocol analysis adjusting for baseline breast cancer risk factors; and had reminded the public that its findings did not apply to women initiating HT in perimenopause or early post-menopause, there would have been minimal controversy, no confusion, and women’s health would not have suffered so dramatically over the ensuing decades.”

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
873.20
自引率
0.10%
发文量
51
审稿时长
1 months
期刊介绍: CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信